MENU

Bring your portfolio to life with these 3 healthcare shares

It certainly has been a great start to the year for the S&P/ASX 200 Health Care (Index: ^AXHJ) (ASX: XHJ). Year-to-date the healthcare index has smashed the market with a whopping 15% gain.

Despite this huge gain I still feel there are a number of healthcare shares which could climb significantly higher over the next 12 months. Here they are:

The Japara Healthcare Ltd (ASX: JHC) share price has fallen 30% in the last 12 months due largely to funding concerns in the aged care sector. This has left the leading aged care operator’s shares changing hands at just over 14x trailing earnings and at a level which I believe provides investors with a good risk/reward. As Australia’s population ages, demand for care is expected to rise strongly. Japara aims to meet this demand with the addition of over 1,100 new greenfield places by FY 2020. This will be an increase of approximately 29% on its current places.

The Monash IVF Group Ltd (ASX: MVF) share price is down 20% since the start of October due to the impact of increased competition. Although competition has heated up in the fertility treatment industry, I think Australia’s second-largest IVF provider will bounce back thanks to the strong underlying demand fundamentals for IVF and women’s imaging services. At just over 15x trailing earnings and providing a trailing fully franked 4.1% dividend, Monash IVF could be worth revisiting in my opinion.

The Ramsay Health Care Limited (ASX: RHC) share price may have jumped 11% in the last 12 months, but I still see significant gains ahead for the private hospital operator. Due to ageing populations across the world, increased chronic disease burden, and improvement in treatments, I think Ramsay is in a great position to grow organically over the next decade. The company also has the potential to grow inorganically through acquisitions and expansions. While 29x trailing earnings may sound expensive, I think its long-term growth prospects more than justify the premium.

Finally, although this fantastic fourth share isn't in the healthcare sector, I do think investors that like to buy and hold shares like Ramsay should consider it. Its huge dividend and explosive growth prospects make it a strong buy in my opinion.

We've just released our #1 dividend pick for 2017. And the winner is...

With its shares up 155% in just the last five years, this 'under the radar' consumer favourite is both a hot growth stock AND our expert's #1 dividend pick for 2017. Now we're pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is click the link below!

Simply click here to receive your copy of our brand-new FREE report, "The Motley Fool's Top Dividend Stock for 2017."

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

HOT OFF THE PRESSES: My #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.